Barclays’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-50
| Closed | – | – | 7821 |
|
|
2018
Q3 | $0 | Hold |
50
| – | – | ﹤0.01% | 7721 |
|
|
2018
Q2 | $0 | Hold |
50
| – | – | ﹤0.01% | 7654 |
|
|
2018
Q1 | $0 | Hold |
50
| – | – | ﹤0.01% | 7662 |
|
|
2017
Q4 | $0 | Hold |
50
| – | – | ﹤0.01% | 7391 |
|
|
2017
Q3 | $0 | Hold |
50
| – | – | ﹤0.01% | 7335 |
|
|
2017
Q2 | $0 | Hold |
50
| – | – | ﹤0.01% | 7290 |
|
|
2017
Q1 | $0 | Hold |
50
| – | – | ﹤0.01% | 7277 |
|
|
2016
Q4 | $0 | Hold |
50
| – | – | ﹤0.01% | 7132 |
|
|
2016
Q3 | $0 | Hold |
50
| – | – | ﹤0.01% | 7102 |
|
|
2016
Q2 | $0 | Hold |
50
| – | – | ﹤0.01% | 7011 |
|
|
2016
Q1 | $0 | Hold |
50
| – | – | ﹤0.01% | 6881 |
|
|
2015
Q4 | $0 | Buy |
+50
| New | +$826 | ﹤0.01% | 7292 |
|
|
2014
Q4 | – | Sell |
-414
| Closed | – | – | 8033 |
|
|
2014
Q3 | $0 | Sell |
414
-3
| -0.7% | -$116 | ﹤0.01% | 8110 |
|
|
2014
Q2 | $17K | Hold |
417
| – | – | ﹤0.01% | 6608 |
|
|
2014
Q1 | $17K | Hold |
417
| – | – | ﹤0.01% | 6697 |
|
|
2013
Q4 | $0 | Hold |
417
| – | – | ﹤0.01% | 8004 |
|
|
2013
Q3 | $33K | Sell |
417
-4,122
| -91% | -$453K | ﹤0.01% | 6297 |
|
|
2013
Q2 | $352K | Buy |
+4,539
| New | +$435K | ﹤0.01% | 4621 |
|
Other funds holding IMUC
Barclays's IMUC Position: Q4 2018 in Review
Barclays sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 50 shares.
Barclays first reported a position in IMUC in Q2 2013 and held it in 18 quarters. The position peaked at $352K in Q2 2013. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.
- Barclays reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
- Barclays sold 50 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018.
- Barclays first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 18 quarters.
- Barclays's ImmunoCellular Therapeutics, Ltd. position peaked at $352K in Q2 2013.
- 3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.
Based on Barclays's 13F filing for Q4 2018, filed 14 Feb 2019.